HARVARD BIOSCIENCE INC
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
HBIO$9.09+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
HARVARD BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenues | $21,774 | $24,512 |
| Cost of revenues | 9,590 | 9,740 |
| Gross profit | 12,184 | 14,772 |
| Sales and marketing expenses | 4,971 | 5,904 |
| General and administrative expenses | 5,185 | 5,963 |
| Research and development expenses | 2,321 | 2,885 |
| Amortization of acquired intangible assets | 1,160 | 1,333 |
| Goodwill impairment - Note 4 | 47,951 | - |
| Other operating expenses - Note 1 | 264 | 966 |
| Total operating expenses | 61,852 | 17,051 |
| Operating loss | (49,668) | (2,279) |
| Other income (expense): | ||
| Interest expense | (802) | (751) |
| Loss on equity securities - Note 6 | - | (1,312) |
| Other expense, net | (324) | (142) |
| Total other expense | (1,126) | (2,205) |
| Loss before income taxes | (50,794) | (4,484) |
| Income tax (benefit) expense | (454) | 210 |
| Net loss | $(50,340) | $(4,694) |
| Loss per share: | ||
| Basic and diluted loss per share | $(1.14) | $(0.11) |
| Weighted-average common shares: | ||
| Basic and diluted | 44,096 | 43,402 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.